BCN057 And BCN512 Wnt/β-Catenin Modulation for Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including surgery, radiation therapy, and chemotherapy, have seen limited advancements and offer modest survival benefits, and there is a need for improved therapies that can modulate the Wnt signaling pathway to treat cancer and other conditions such as fibrosis and inflammatory diseases.
Innovation Solution
The use of novel small molecules BCN057 and BCN512, and their analogs, to modulate Wnt/β-catenin signaling, which are administered to treat cancer, fibrosis, and other conditions by inhibiting SFRP activity and modulating Wnt signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments (surgery, radiation therapy, chemotherapy) are used, then cancer can be treated, but survival benefits are limited and side effects are significant
Solution Approach 1:
The patent applies parameter changes by modifying the Wnt signaling pathway parameters through small molecule compounds (BCN057 and BCN512). These compounds change the biochemical parameters of cancer cell behavior by inhibiting β-catenin-dependent signaling, thereby altering cell proliferation, survival, and differentiation parameters to achieve therapeutic effects with different side effect profiles compared to conventional treatments
Solution Approach 2:
The patent uses small molecule compounds as intermediaries that mediate between the Wnt signaling pathway and therapeutic outcomes. These compounds act as molecular mediators that specifically target and modulate the Wnt/β-catenin pathway, providing a more precise mechanism of action compared to the broad-spectrum effects of conventional chemotherapy and radiation therapy
2Adaptability or versatility
If Wnt pathway modulators are used to treat cancer, then new therapeutic opportunities are created, but the mechanisms and compounds are not yet fully established
Solution Approach 1:
The patent applies preliminary action by establishing and validating the mechanism of Wnt pathway modulation before clinical application. The patent provides preliminary data on the effects of BCN057 and BCN512 on Wnt signaling in various cell lines and disease models, creating a foundation for further development and clinical translation of this therapeutic approach
Solution Approach 2:
The patent demonstrates universality by showing that Wnt pathway modulators can treat multiple different conditions including various cancers (colorectal, pancreatic, lung, breast), fibrotic diseases, and inflammatory conditions. This multi-functional approach expands treatment options across different disease types while using a common mechanistic target
Data Source
AI summary
The present disclosure is directed to methods of treating or ameliorating various conditions by the administration of a BCN057, BCN512 or analogs of these compounds. The compounds can be used to reduce tumor burden in cancers, including pancreatic cancer and gastrointestinal (GI) cancer. The compounds can also be used to protect against chemotherapy induced toxicity to the GI tract. Further, they can be used to treat fibrosis and various inflammatory conditions. Analogs of BCN057 and BCN512 are also described.